Bedminster, New Jersey – Former President Donald Trump is hosting a significant fundraiser for the pro-Trump super PAC, MAGA Inc., at his Bedminster golf club, with sources indicating a target of approximately $25 million. Among the expected attendees is Albert Bourla, CEO of Pfizer, a presence that comes as Trump intensifies his push for pharmaceutical companies to lower U.S. drug prices.
The fundraiser coincides with renewed efforts by Trump to implement a "most favored nation" drug pricing policy. Just yesterday, Trump sent letters to pharmaceutical companies, including Pfizer, demanding that they "lower U.S. drug prices to more evenly match what other countries pay," according to a tweet from Jennifer Jacobs. This initiative aims to align American drug costs with the lowest prices paid by other developed nations.
Trump's administration previously issued an executive order in May 2025, titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which sought to bring U.S. drug prices in line with those paid by comparable countries. The White House has sent letters to 17 drug companies, requesting commitments within 60 days to adhere to this "most favored nation" policy. This policy reflects Trump's long-standing criticism that Americans pay disproportionately high prices for medications compared to other nations.
MAGA Inc., established in September 2022, serves as a primary fundraising vehicle for Donald Trump, capable of raising and spending unlimited funds to support his political endeavors. Recent reports indicate the super PAC has been actively engaged in high-dollar fundraising events, accumulating substantial reserves to influence upcoming elections and support Trump's agenda. The attendance of a major pharmaceutical executive like Bourla at such an event underscores the complex relationship between political fundraising and industry policy.
Pfizer CEO Albert Bourla has had a notable, at times contentious, relationship with Donald Trump, particularly concerning vaccine development during the previous administration and ongoing discussions around drug pricing. Bourla's presence at the fundraiser suggests continued engagement between key industry leaders and the former president, even as Trump advocates for policies that could significantly impact pharmaceutical revenues. The broader implications of such a policy could reshape the landscape of drug pricing and market access in the United States.